CR20110380A - PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH (DIVISIONAL EXP. 8266) - Google Patents
PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH (DIVISIONAL EXP. 8266)Info
- Publication number
- CR20110380A CR20110380A CR20110380A CR20110380A CR20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A CR 20110380 A CR20110380 A CR 20110380A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- divisional
- exp
- cellular growth
- abnormal cellular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto de la fórmula I en la que R2- R4 son como se han definido en esta memoria. Tales nuevos derivados de pirimidina son útiles en el tratamiento del crecimiento celular anormal, tal como el cáncer, en los mamíferos. Esta invención se refiere también a un método de uso de tales compuestos en el tratamiento del crecimiento celular anormal en los mamíferos especialmente en los seres humanos, y a composiciones farmacéuticas que contienen tales compuestos.The present invention relates to a compound of the formula I in which R2-R4 are as defined herein. Such new pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals especially in humans, and to pharmaceutical compositions containing such compounds.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43567002P | 2002-12-20 | 2002-12-20 | |
US50074203P | 2003-09-05 | 2003-09-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110380A true CR20110380A (en) | 2011-08-08 |
Family
ID=32685406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8266A CR8266A (en) | 2002-12-20 | 2006-03-02 | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH |
CR20110380A CR20110380A (en) | 2002-12-20 | 2011-07-06 | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH (DIVISIONAL EXP. 8266) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8266A CR8266A (en) | 2002-12-20 | 2006-03-02 | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH |
Country Status (31)
Country | Link |
---|---|
US (4) | US7109335B2 (en) |
EP (1) | EP1625121B1 (en) |
AP (1) | AP2385A (en) |
AR (1) | AR043682A1 (en) |
AT (1) | ATE458731T1 (en) |
AU (2) | AU2003285614B2 (en) |
CA (1) | CA2529611C (en) |
CR (2) | CR8266A (en) |
CY (1) | CY1110069T1 (en) |
DE (1) | DE60331479D1 (en) |
DK (1) | DK1625121T3 (en) |
DO (1) | DOP2003000793A (en) |
EA (1) | EA013248B1 (en) |
EC (1) | ECSP066406A (en) |
ES (1) | ES2338545T3 (en) |
GE (1) | GEP20084357B (en) |
IL (1) | IL172047A (en) |
MX (1) | MXPA06002608A (en) |
MY (1) | MY142109A (en) |
NL (1) | NL1025067C2 (en) |
NZ (1) | NZ543719A (en) |
OA (1) | OA13309A (en) |
PA (1) | PA8593001A1 (en) |
PE (1) | PE20041016A1 (en) |
PL (1) | PL379330A1 (en) |
PT (1) | PT1625121E (en) |
RS (1) | RS20060097A (en) |
SI (1) | SI1625121T1 (en) |
TN (1) | TNSN06074A1 (en) |
TW (1) | TWI283673B (en) |
WO (1) | WO2004056807A1 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GEP20084357B (en) | 2002-12-20 | 2008-04-29 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
DE10349423A1 (en) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments |
GEP20104875B (en) * | 2004-05-14 | 2010-01-11 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0510963A (en) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | pyrimidine derivatives for the treatment of abnormal cell growth |
EP1756090A1 (en) * | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005111022A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
JP4812763B2 (en) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof |
US20090118316A1 (en) * | 2004-06-21 | 2009-05-07 | Pfzer Inc. | Methods for Augmenting Bone |
EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
BRPI0618011A2 (en) * | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | compound or a pharmaceutically acceptable salt thereof, process for the preparation thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an antiproliferative effect and a pro-apoptotic effect in an animal warm-blooded to treat disease and to produce a jak inhibiting effect on a warm-blooded animal |
EP1966192B1 (en) * | 2005-12-01 | 2012-10-17 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
DE602007012363D1 (en) | 2006-10-19 | 2011-03-17 | Rigel Pharmaceuticals Inc | 2,4-pyridimediamine derivatives as inhibitors of JAK KINASES for the treatment of autoimmune diseases |
DE102007010801A1 (en) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Use of new and known 2,4-diaminopyrimidine derivatives as fungicides, especially for controlling phytopathogenic fungi |
WO2008115443A1 (en) * | 2007-03-16 | 2008-09-25 | University Of Florida Research Foundation | Kinase protein binding inhibitors |
CN101678215B (en) * | 2007-04-18 | 2014-10-01 | 辉瑞产品公司 | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
KR101294731B1 (en) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | Array substrate, display panel having the array substrate and method of manufacturing the array substrate |
KR20100049068A (en) | 2007-07-17 | 2010-05-11 | 리겔 파마슈티칼스, 인크. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
CL2009000600A1 (en) * | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Use of diaminopyrimidine compounds as phytosanitary agents; diaminopyrimidine compounds; its preparation procedure; agent that contains them; procedure for the preparation of said agent; and method for combating pests of animals and / or harmful plant pathogenic fungi. |
EP2161259A1 (en) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Haloalkyl substituted Diaminopyrimidine |
US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
JP5539518B2 (en) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
EP2395001A1 (en) | 2010-05-21 | 2011-12-14 | Chemilia AB | Novel pyrimidine derivatives |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
DE102010034699A1 (en) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | pyrimidine derivatives |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
CN103534241B (en) | 2011-02-17 | 2015-11-25 | 癌症疗法Crc私人有限公司 | Fak inhibitor |
CA2827172C (en) | 2011-02-17 | 2019-02-26 | Cancer Therapeutics Crc Pty Limited | Selective fak inhibitors |
EP2502924A1 (en) | 2011-03-24 | 2012-09-26 | Chemilia AB | Novel pyrimidine derivatives |
CA2830129C (en) | 2011-03-24 | 2016-07-19 | Chemilia Ab | Novel pyrimidine derivatives |
DE102011111400A1 (en) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclic heteroaromatic compounds |
CA2850594C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
AU2012357038B2 (en) | 2011-12-23 | 2016-05-12 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
EP2711365A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
CN116888100A (en) * | 2021-04-08 | 2023-10-13 | 杭州阿诺生物医药科技有限公司 | High-activity HPK1 kinase inhibitor |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507146A (en) | 1982-12-28 | 1985-03-26 | Ciba-Geigy Corporation | 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
DE4029650A1 (en) | 1990-09-19 | 1992-03-26 | Hoechst Ag | New 2-aryl:amino-pyrimidine derivs. - contg. alkynyl gp., useful as fungicides |
CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
DE4131184A1 (en) | 1991-09-19 | 1993-03-25 | Bayer Ag | WATER-BASED, SOLVENT-FREE AND EMULSIFY-FREE MICROBICIDES ACTIVE SUBSTANCE COMBINATION |
WO1993010086A1 (en) | 1991-11-13 | 1993-05-27 | MTA Központi Kémiai Kutató Intézete | Process for preparing n-(arylsulphonyl)-carbamide acid derivates and intermediates useful for carrying out this process |
DE4137291A1 (en) | 1991-11-13 | 1993-05-19 | Bayer Ag | METHOD FOR CONTINUOUSLY IMPLEMENTING HALOGENPYRIMIDINES WITH AMINES |
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
FR2686339B1 (en) | 1992-01-22 | 1994-03-11 | Adir Cie | NOVEL NAPHTHALENIC AMIDES AND SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
PT642502E (en) | 1992-05-22 | 2000-12-29 | Du Pont | IMIDAZOLINONES FUNGICIDES |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
PL326083A1 (en) | 1995-10-02 | 1998-08-17 | Hoffmann La Roche | Novel pyrimidin derivatives as antagonists of 5ht 2c receptor |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
ID19430A (en) | 1996-07-13 | 1998-07-09 | Glaxo Group Ltd | COMPOUND HETEROSICLIC COMPOUND |
ID19609A (en) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | HETEROSICLIC COMPOUNDS |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
CZ292806B6 (en) | 1996-08-06 | 2003-12-17 | Pfizer Inc. | Pyrido- or pyrimido-6,6- or -6,7-bicyclic derivatives and pharmaceutical compositions based thereon |
PL332187A1 (en) | 1996-09-04 | 1999-08-30 | Pfizer | Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf) |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
DE19701931C1 (en) | 1997-01-21 | 1998-05-28 | Siemens Ag | Method for the detection of synchronicity between several digital measurement series with the help of a computer |
IL131475A0 (en) | 1997-02-19 | 2001-01-28 | Berlex Lab | N-heterocyclic derivatives as nos inhibitors |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
CZ20001709A3 (en) | 1997-11-11 | 2001-12-12 | Pfizer Products Inc. | Thienopyrimide and thienopyridine derivatives, pharmaceutical compositions and treatment methods based thereon |
ATE245641T1 (en) | 1998-02-17 | 2003-08-15 | Tularik Inc | ANTIVIRAL PYRIMIDINE DERIVATIVES |
AU5438299A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
EP1950201A1 (en) | 1998-09-29 | 2008-07-30 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
KR20030024659A (en) * | 2000-02-17 | 2003-03-26 | 암겐 인코포레이티드 | Kinase Inhibitors |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
KR20080009294A (en) | 2000-03-13 | 2008-01-28 | 와이어쓰 홀딩스 코포레이션 | Pharmaceutical composition for treating or inhibiting colonic polyps comprising cyanoquinolines |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US7160896B2 (en) | 2000-07-07 | 2007-01-09 | Cancer Research Technology Limited | Therapeutic acridone and acridine compounds |
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
WO2002012228A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Cinnoline compounds |
AU7993801A (en) | 2000-08-09 | 2002-02-18 | Astrazeneca Ab | Chemical compounds |
AU2001278609B2 (en) | 2000-08-21 | 2005-04-14 | Astrazeneca Ab | Quinazoline derivatives |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Polyarylcarboxamides useful as lipid lowering agents |
EP1343782B1 (en) | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
IL159120A0 (en) | 2001-05-29 | 2004-05-12 | Schering Ag | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003020276A1 (en) | 2001-08-30 | 2003-03-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
DE50212771D1 (en) * | 2001-10-17 | 2008-10-23 | Boehringer Ingelheim Pharma | PYRIMIDIN DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PREPARATION |
WO2003032994A2 (en) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel tri-substituted pyrimidines, method for production and use thereof as medicament |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
ATE470656T1 (en) | 2002-02-05 | 2010-06-15 | Wyeth Llc | METHOD FOR PRODUCING N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS |
DE10205336A1 (en) | 2002-02-07 | 2003-08-21 | Bdd Group Holding Ag Zug | Deuterated biphenyl derivatives |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
NZ539488A (en) | 2002-12-20 | 2008-03-28 | Arakis Ltd | Benzoxazocines and their use as monoamine-reuptake inhibitors |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GEP20084357B (en) | 2002-12-20 | 2008-04-29 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0414059B8 (en) | 2003-09-05 | 2021-05-25 | Pfizer Prod Inc | selective synthesis of substituted pyrimidines in cf3 |
WO2005111022A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
EP1756090A1 (en) | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidine derivatives for the treatment of abnormal cell growth |
BRPI0510963A (en) | 2004-05-14 | 2007-11-20 | Pfizer Prod Inc | pyrimidine derivatives for the treatment of abnormal cell growth |
-
2003
- 2003-12-08 GE GEAP20039074A patent/GEP20084357B/en unknown
- 2003-12-08 PL PL379330A patent/PL379330A1/en not_active Application Discontinuation
- 2003-12-08 EP EP03778613A patent/EP1625121B1/en not_active Expired - Lifetime
- 2003-12-08 AT AT03778613T patent/ATE458731T1/en active
- 2003-12-08 AU AU2003285614A patent/AU2003285614B2/en not_active Expired
- 2003-12-08 DE DE60331479T patent/DE60331479D1/en not_active Expired - Lifetime
- 2003-12-08 EA EA200600122A patent/EA013248B1/en not_active IP Right Cessation
- 2003-12-08 ES ES03778613T patent/ES2338545T3/en not_active Expired - Lifetime
- 2003-12-08 CA CA002529611A patent/CA2529611C/en not_active Expired - Lifetime
- 2003-12-08 WO PCT/IB2003/005883 patent/WO2004056807A1/en active Application Filing
- 2003-12-08 OA OA1200600067A patent/OA13309A/en unknown
- 2003-12-08 SI SI200331771T patent/SI1625121T1/en unknown
- 2003-12-08 PT PT03778613T patent/PT1625121E/en unknown
- 2003-12-08 MX MXPA06002608A patent/MXPA06002608A/en active IP Right Grant
- 2003-12-08 DK DK03778613.4T patent/DK1625121T3/en active
- 2003-12-08 RS YUP-2006/0097A patent/RS20060097A/en unknown
- 2003-12-08 AP AP2005003438A patent/AP2385A/en active
- 2003-12-11 US US10/733,215 patent/US7109335B2/en not_active Expired - Lifetime
- 2003-12-16 TW TW092135619A patent/TWI283673B/en not_active IP Right Cessation
- 2003-12-17 MY MYPI20034835A patent/MY142109A/en unknown
- 2003-12-17 DO DO2003000793A patent/DOP2003000793A/en unknown
- 2003-12-18 PA PA20038593001A patent/PA8593001A1/en unknown
- 2003-12-18 NL NL1025067A patent/NL1025067C2/en not_active IP Right Cessation
- 2003-12-18 AR ARP030104715A patent/AR043682A1/en unknown
-
2004
- 2004-01-05 PE PE2004000041A patent/PE20041016A1/en not_active Application Discontinuation
- 2004-12-08 NZ NZ543719A patent/NZ543719A/en not_active IP Right Cessation
-
2005
- 2005-11-20 IL IL172047A patent/IL172047A/en active IP Right Grant
-
2006
- 2006-03-02 CR CR8266A patent/CR8266A/en unknown
- 2006-03-03 TN TNP2006000074A patent/TNSN06074A1/en unknown
- 2006-03-03 EC EC2006006406A patent/ECSP066406A/en unknown
- 2006-08-17 US US11/506,689 patent/US7351712B2/en not_active Expired - Lifetime
-
2008
- 2008-03-31 US US12/059,889 patent/US7674796B2/en not_active Expired - Lifetime
- 2008-07-29 US US12/181,991 patent/US7741336B2/en not_active Expired - Lifetime
-
2009
- 2009-08-14 AU AU2009208172A patent/AU2009208172B2/en not_active Expired
-
2010
- 2010-04-20 CY CY20101100360T patent/CY1110069T1/en unknown
-
2011
- 2011-07-06 CR CR20110380A patent/CR20110380A/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110380A (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH (DIVISIONAL EXP. 8266) | |
HN2005000212A (en) | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
UY28135A1 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
CU23413B7 (en) | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS | |
UY28894A1 (en) | PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH | |
ECSP088563A (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
PA8777101A1 (en) | DERIVATIVES OF SULFONIL AMIDA FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
ECSP045146A (en) | SMALL MOLECULES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
AR028985A1 (en) | COMPOUNDS DERIVED FROM QUINOLIN-2-ONA- SUBSTITUTED WITH HETEROARILO USEFUL AS ANTI-VANEER AGENTS, PROCESSING PROCESSING OF DISEASES USING SUCH COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING IT | |
AR053412A1 (en) | INHIBITING COMPOUNDS OF INTERACTION BETWEEN MDM2 AND P53, A METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND TO MANUFACTURE MEDICATIONS | |
GT199900070A (en) | DERIVATIVES OF ISOTIAZOLE, USEFUL AS ANTI-CANCER AGENTS. | |
UY28695A1 (en) | DERIVATIVES OF DIFENILAZETIDONA | |
AR018162A1 (en) | SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION | |
PA8589801A1 (en) | AMINOALCOXYINDOLS | |
UY28136A1 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
NI200500205A (en) | "PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ANORMA CELLULAR GROWTH." | |
AR036110A1 (en) | EUROTINONA AND DERIVATIVES OF THE SAME, PROCEDURE FOR THEIR PREPARATION, A MICROORGANISM, PHARMACEUTICAL COMPOSITIONS, PROCEDURE FOR THEIR PRODUCTION, THE USE OF SUCH DERIVATIVES AND COMPOSITIONS FOR THE PREPARATION OF DRUGS, AND USE OF SUCH MICROORGANISM | |
CL2004000744A1 (en) | METHOD FOR PREPARING DERIVATIVES OF PHENYLAMINOQUINAZOLINS; INTERMEDIARY COMPOUND; AND ITS PREPARATION METHOD. | |
AR033457A1 (en) | PIPERAZINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE TO PREPARE SUCH COMPOSITION AND PROCEDURE TO PREPARE IT | |
DOP2003000786A (en) | BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH. | |
DOP2005000086A (en) | PIRIMIDINE DERIVATIVES TO TREAT ANOMALO CELLULAR GROWTH | |
UY28131A1 (en) | BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
CU20060216A7 (en) | PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH | |
SV2006002113A (en) | PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH REF. PC32279A | |
ECSP972324A (en) | DERIVATIVES OF CONDENSED BICYCLIC PIRIMIDINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |